-The Hindu In the area of intellectual property, public health and Access to Medicines, the Narendra Modi government should consider its independence to be of the utmost importance. Strong government leadership as well as flexible intellectual property systems are needed in order to effectively combat drug-resistant tuberculosis (DR-TB) and HIV and also antimicrobial resistance and non-communicable diseases. This is true not only for India but also countries which rely on affordable generic...

-The Hindu Patients face discrimination because public health systems and schools are not equipped to deal with the problem Bengaluru: “The cost of my daughter's treatment is around Rs. 1 crore per annum. If it were not for the aid of a United States-based foundation, I would not be able to help her,” said Prasanna B. Shirol, founder-director, Organisation for Rare Diseases India. His teenage daughter suffers from Pompe Disease, a rare...

-Kafila.org The last few months have seen an unusual public engagement around questions of secularism, freedom of speech, sedition and the like, with furious debates everywhere from our campuses, streets and TV studios to the floor of Parliament. The budget session has been enlivened by scenes of high drama, with the leading lights of the Treasury benches bringing colour, sound and fury to their tutorials on patriotism and nationalism. While these high-decibel...

-The Telegraph New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions. The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not...

-TheWire.in The government appears bent on decisively abandoning the earlier consensus of adherence to public health goals. In what is widely being hailed as an extraordinary victory for the multinational pharmaceutical industry over the Indian government, the US-India Business Council (USIBC), in its submission to the United States Trade Representative (USTR), reports that the Indian government has “privately assured” the industry that it would not use compulsory licences (CLs) for commercial purposes....